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HIV/AIDS is a leading cause of mortality and morbidity worldwide. In spite of successful interventions and treatment protocols,
an HIV vaccine would be the ultimate prevention and control strategy. Ever since identification of HIV/AIDS, there have been
meticulous efforts for vaccine development. The specific aim of this paper is to review recent vaccine efficacy trials and associated
advancements and discuss the current challenges and future directions. Recombinant DNA technologies greatly facilitated
development of many viral products which were later incorporated into vectors for effective vaccines. Over the years, a number of
scientific approaches have gained popularity and include the induction of neutralizing antibodies in late 1980s, induction of CD8
T cell in early 1990s, and combination approaches currently. Scientists have hypothesized that stimulation of right sequences of
somatic hypermutations could induce broadly reactive neutralizing antibodies (bnAbs) capable of effective neutralization and viral
elimination. Studies have shown that a number of host and viral factors affect these processes. Similarly, eliciting specific CD8 T
cells immune responses through DNA vaccines hold future promises. In summary, future studies should focus on the continuous
fight between host immune responses and ever-evasive viral factors for effective vaccines.
1. Introduction
Since the first recognized cases of the Acquired Immunod-
eficiency Syndrome (AIDS) came to light in the early 1980s
and the discovery of the human immunodeficiency virus
(HIV) soon after, HIV/AIDS has become a leading cause of
mortality and morbidity worldwide. In the year 2013, global
estimations showed that about 35 million people are living
with HIV infection [1]. Since the initial identification and
characterization of the disease, about 78 million people have
become infected and 39 million people have died from AIDS
related conditions [2]. However, the incidence of this disease
has fallen by 38% since the year 2001 [3]. About 2.1 million
people have become newly infected withHIV in the year 2013
compared to 3.4 million in the year 2001 [3]. AIDS related
deaths have plummeted by 35% since the peak in the year
2005 [3]. In 2013, 1.5 million people died from AIDS related
conditions compared to 2.4 million in the year 2005 [3].
Since the advent of antiretroviral medications, HIV infection
has become a chronic disease with decreasing incidence and
increasing prevalence.
In the year 2013, about 12.9 million people were receiving
some form of antiretroviral therapy and constituted only
37% of all infected cases globally [4]. According to global
estimates, about $19.1 billion was spent on HIV/AIDS and
related conditions in the year 2013 and is estimated to
increase to $24 billion by the year 2015 [5, 6]. This is a
great burden on both developed and developing economies
becausemore than 50% of total expenses are directed towards
underdeveloped nations with decreased productive capacity
and increasedHIV associated life loss years.Though there are
a number of effective prevention interventions and treatment
methods like preexposure prophylaxis and antiretroviral
therapy, researchers have always been zealous about HIV
vaccine as the ultimate HIV prevention and control strategy.
In spite of such efforts, there are only few studies that have
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shown successful results. The specific aim of this paper
is to review recent vaccine efficacy trials and associated
advancements about HIV vaccines and discuss the current
challenges and future direction of this initiative.
2. Search Strategy and Selection Criteria
We followed a narrative review method to summarize recent
advances in HIV vaccine development. We searched the
electronic databases PubMed, EMBASE, Ovid, and Google
Scholar for articles published between January 1985 and
September 2015 (30 years) by combining the following
search terms: “HIV”, “AIDS”, “vaccine”, “clinical trials”,
“broadly neutralizing antibodies”, “CD8 T cells”, “CD4 T
cells”, “antibody-dependent cell-mediated cytotoxicity”, and
“antibody-dependent cell-mediated viral inhibition”.
3. Vaccine Efficacy Trials
Ever since HIV was formally identified as the cause of AIDS,
there have been ongoing efforts on vaccines against the
disease. On April 24, 1984, the US Secretary of Health and
Human Services, Margaret Heckler, announced that vaccines
will be researched and made ready for preliminary testing
by the year 1986 [7]. However, this initial optimism was
criticized by many eminent researchers because it failed to be
coherent with existing knowledge about the pathophysiology
and the mechanism of the virus itself. Traditional approaches
of using live attenuated orwhole inactivated viruseswere con-
sidered unsafe because of the risk of permanently integrating
proviral DNA within host chromosomes [8]. Advancements
in vaccine development had to wait until mid-1980s when
recombinant DNA technologies were becoming available for
research applications. Following the success of recombinant
Hepatitis B vaccine, recombinant DNA technologies were
also being researched for HIV vaccines [9]. Rapid advances
in the pathophysiology and molecular mechanisms of HIV
enabled many structural components and proteins to be
discovered and artificially synthesized through recombinant
DNA technology. The culmination was the cloning and
sequencing of HIV genome which led scientists to believe
that an effective vaccine could be developed in the future.
However, all these efforts came to a standstill with growing
knowledge about extreme mutability and immune evasion
mechanisms of existing HIV strains [10]. This was further
complicated by the fact that neutralizing antibodies had no
protective effects and their titers were similar among asymp-
tomatic carriers and patients with active disease [11]. The
exact mechanism of immunity against HIV is a puzzle and
still remains unsolved. Currently 3 scientific paradigms have
attracted researchers and include induction of neutralizing
antibodies; induction of CD8 T cell mediated immunity; and
combination approaches [12].
In spite of many nonmaterializing studies, hopes
were renewed when a handful of studies presented newer
approaches for inducing effective humoral and cell mediated
immune responses against the virus. In a clinical trial done by
Belshe et al. [13] in 1998, it was observed that live attenuated
canarypox virus expressing HIV antigens were capable of
inducing CD8 cytotoxic T cells against Env or Gag expressing
target cells in 64% of the volunteers. It was also observed
that the vaccine elicited profound neutralizing antibodies
after vaccine priming and subunit boosting strategies.
This study established the prime-boost concept for future
HIV vaccine research. This study also showed that such
prime-boost regimens induced both cellular and humoral
responses. However, in another large scale clinical trial done
among 330 healthy volunteers, canarypox vaccine (vCP1452)
failed to induce adequate CD8 cytotoxic T lymphocyte
responses or neutralizing antibodies measured by enzyme-
linked immunoassay (ELISA) thereby dampening the hopes
generated in previous studies [14].
In a study (RV144) done among 16,402 healthy partici-
pants to test the efficacy of recombinant canarypox vector
vaccine (priming by four doses of ALVAC-HIV [vCP1521]
andbooster by twodoses ofAIDSVAXB/E), a vaccine efficacy
of 31.2% (95%CI, 1.1 to 52.1) was observed [15].The study also
suggested that antibodies (IgG
1
and IgG
3
) directed towards
V1/V2 region of gp120 showed some protective effects against
transmission of HIV-1 infection. In addition, IgA antibodies
towards envelope proteins were inversely associated with
mucosal HIV-1 transmission. However, vaccination did not
affect the immunological (CD4 cell count) and virological
markers (HIV viral RNA) in subsequently diagnosed HIV
infected participants. In spite of modest results shown by
RV144 trial, the reasons for the decreased risk of infections
in vaccinated subjects with antibodies against V1/V2 region
of gp120 are a remarkable finding. Thus, V1/V2 constitutes
an important component in the process of viral integration
into the host cell. V1/V2 region of gp120 interacts with CD4
receptors as well as gut mucosal homing integrin binding
site 𝛼4𝛽7 of CC chemokine receptor 5 (CCR5) coreceptor,
resulting in incorporation of the viral genome into the host
cell [16, 17].
As a follow-up of RV144 study, the HVTN P5 was
proposed to research a pox-protein based HIV vaccine. The
potential candidates selected were ALVAC-C (expressing
ZM96 gp120 (clade C strain) linked to gp41, and gag and pro
clade B LAI strain); NYVAC-C (bivalent highly attenuated
vaccinia virus expressing clade C ZM96 gp140 and ZM96
Gag-CN54 Pol-Nef fusion proteins); Gp120 protein + MF59
(clade C TV1 gp120 Env and clade C 1086 gp120 Env with
MF59 adjuvant); Gp120 protein + ASO1B (clade C TV1 gp120
Env and clade C 1086 gp120 Env with ASO1B adjuvant); and
DNA-C (trivalent DNA expressing clade C ZM96 Gag and
gp140, and a CN54 Pol-Nef fusion construct). This multisite
international study selected sites in SouthernAfrica andThai-
land. This study has prospects for next generation clade C-
adapted vaccines with more effective priming immunogens
and adjuvants with potent immunological properties.
In another large scale multisite study (HVTN 505) done
among 2,504 participants, a 6-plasmid DNA vaccine with
embedded gag/pol/env/nef proteins from clades A, B, and
C was administered at 0, 4, and 8 weeks [18]. This was
followed by booster vaccine, rAd5, expressing clade B gag-pol
fusion protein and env glycoproteins from clades A, B, and C.
Results showed that the vaccine was not efficient in spite of its
acceptable side effect profile and the study was discontinued
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Table 1: HIV vaccine efficacy trials.
Study Site Vaccine Volunteers Vaccine to placeborandomization Results
Vax004 USA andNetherlands AIDSVAX B/B
󸀠 gp120 with alum 5,100 MSM and300 women 2 : 1
No vaccine
efficacy
Vax003 Thailand AIDSVAX B/E gp120 with alum 2,500 men andwomen IDUs 1 : 1
No vaccine
efficacy
HVTN 502
Step trial
North America,
the Caribbean,
South America,
and Australia
MRKAd5 HIV-1 gag/pol/nef
trivalent vaccine based on
adenovirus type 5
3,000 MSM and
heterosexual
women and men
1 : 1 No vaccineefficacy
RV144 Thailand
Recombinant canarypox vector
vaccine (ALVAC-HIV [vCP1521])
and recombinant glycoprotein 120
subunit vaccine (AIDSVAX B/E)
16,402
community-risk
men and women
1 : 1
31.2% vaccine
efficacy at 42
months
HVTN 503
Phambili trial South Africa
MRKAd5 HIV-1 gag/pol/nef
trivalent vaccine based on
adenovirus type 5
801 heterosexual
men and women 1 : 1
No vaccine
efficacy
HVTN 505 USA 6-plasmid DNA vaccine and rAd5vector boost
2,504 men or
transgender
women who have
sex with men
1 : 1 No vaccineefficacy
HIV-V-A004
USA, Rwanda,
South Africa,
Thailand, and
Uganda
Homologous Ad26 mosaic vector
regimens or Ad26 mosaic and MVA
mosaic heterologous vector
regimens, with high-dose, low-dose
or no clade C gp140 protein plus
adjuvant
400 men and
women — Results awaited
HVTN 100 South Africa Clade C ALVAC-HIV (vCP2438)and bivalent subtype C gp120/MF59
252 men and
women 5 : 1 Results awaited
HVTN 702 South Africa ALVAC-HIV and bivalent subtypeC gp120/MF59
5,400 men and
women 1 : 1 Results awaited
HVTN
703/HPTN 081
South America
and Sub-Saharan
Africa
VRC01 broadly neutralizing
monoclonal antibody
2400 MSM and
transgender and
1500 women
2 : 1 Results awaited
Note: MSM: men who have sex with men; IDUs: IV drug users.
for the same reasons.This study also revealed that DNA/rAd5
vaccine regimen did not produce any changes in the rate of
HIV transmission or plasma viral load. Table 1 shows the list
of all HIV vaccine efficacy trials.
4. Broadly Reactive Neutralizing
Antibodies (bnAbs)
Protective immune response in HIV infection is an ultimate
challenge because of the characteristics of the virus itself.
HIV virus mutates very rapidly leading to many changes in
the envelope proteins within a short time span. A vaccine
therefore should elicit a number of antibodies capable of
neutralizing many genetically different strains. Majority of
HIV infected patients show a prompt monoclonal type anti-
body response capable of affording some levels of protection
against the virus. However, the virus develops resistance to
these antibodies and thrives in the host superseding the
humoral and cellular immune responses. Notable exceptions
to this are nonconventional bnAbs which are observed in
a very small percentage of HIV infected individuals [19].
Even in those individuals who produce bnAbs, only about
a quarter are capable of inducing cross-reacting antibodies
with adequate breadth and potency measured by standard-
ized neutralization assays [20]. Such bnAbs are known to
develop during the first three years of natural infection.
Current researchers opine that vaccine regimens should
focus on inducing useful bnAbs for neutralization of the
viral strains thereby providing high levels of protection.
Though this is very promising, bnAbs also have shortcom-
ings. BnAbs are very rarely produced and the mechanisms
for inducing them through feasible vaccination regimes are
not yet fully understood. BnAbs undergo extensive somatic
hypermutation thereby developing extreme specificity for
viral strains as well as increasing the breadth and potency
of HIV viral neutralizations [21]. However, it is difficult
to induce bnAbs production because of several levels of
somatic hypermutations needed for the process which takes
months to years, by which time the virus develops newer and
resistant mutations [21, 22]. Researchers have also expressed
4 Journal of Immunology Research
concerns about bnAbs being polyreactive or autoreactive and
potentially harmful, and therefore balancing the beneficial
versus adverse effects needs further consideration [23]. Such
lineages of B cells and plasma cells producing autoreactive
antibodies are also eliminated through natural apoptotic
mechanisms thus terminating the production andmaturation
of bnAbs.
Currently, many neutralizing antibody targets are being
researched as potential candidates for inducing bnAbs pro-
duction. These include receptor binding sites on gp120 for
CD4 receptors and CCR5 or CXCR4 coreceptors; variable
regions like V1, V2, and V3 on gp120; and binding sites on
gp41 molecules such as conserved helices and membrane-
proximal external region (MPER) of gp41 [24]. In a study
done among rhesus macaques, it was observed that pas-
sively administered b12 bnAb provided adequate protection
against huge doses of simian-human immunodeficiency virus
(SHIV) inoculated into these animals [25]. This study pos-
tulates that affordable levels of neutralization and protection
against HIV can be achieved in humans through passive
administration of bnAbs. This would be more effective in
humans because, compared to experimental animals, humans
experience much lower levels of viral transmission through
unprotected sex and other means of transmission.This study
provides hope for passive immunization schedules because
a Cox proportional hazard ratio of 21.3 (95% CI: 1.7–260.9)
was observed for b12 bnAb compared to control antibodies
thereby affording 21 times more protection from SHIV
challenge [25]. However, SHIV and HIV cannot be entirely
compared because of differences in receptors involved in
viral integration. Similarly, a sequel to this study by the
same researcher showed that another bnAb, 2G12, offered
stronger protection than b12 with serum neutralizing titers as
high as 1 : 1, compared to approximately 1 : 100 for b12 bnAb
[26]. This has been ascribed to immediate antibody-virus
neutralization by 2G12, compared to much slower processes
by b12 bnAb. This study stresses the importance of 2G12 as
very effective prevention strategy since it provides immediate
protection against target cell infection and integration of
the virus. However, other studies refute these claims and
demonstrate that both b12 and 2G12 did not achieve the
expected level of neutralization. In a study by Hraber et
al., [27] it was observed that b12 and 2G12 in 50 𝜇g/mL
concentrations neutralized only 29.4% and 20.2% of total
number of strains of viruses tested in the study.
Another studywas done among rhesusmacaques in order
to estimate the effects of passive administration of bnAbs.
This study suggested that the administration of 5mg/kg
of PGT121 antibody produced complete neutralization of
SHIVSF162P3 strains and similar effects were found with
1mg/kg doses [28]. However, with 0.2mg/kg of PGT121
and placebo antibodies the macaques started to get infected
with SHIVSF162P3. This study concludes that bnAbs provide
total protection against viral transmissionwhen administered
passively in sufficient doses. A number of animal studies
have shown that bnAbs produce therapeutic neutralization
of viruses in infected animals. In the long run, bnAbs could
evolve into a complimentary therapeuticmodality in addition
to antiretroviral medications and preventive approaches. In
a study by Klein et al. [29], the effects of 5 bnAbs were
tested inmicewithHIV-1YU2-infection.The antibodies tested
included 45-46G54W, PG16, PGT128, 10-1074, and 3BC176.
The study showed a net decrease of 1.1 log
10
for PGT128,
1.5 log
10
for 10-1074, 0.23 log
10
for PG16, 0.56 log
10
for 45-
46
G54W, and no effects for 3BC176. However, the viremia
returned to untreated levels within 14–16 days after the
administration of these passive antibodies in all except
one mice. Thus, bnAbs produced only transient decrease
in viral load in humanized mice with HIV-1YU2-infection.
The study concludes that, in the future, advancements and
combinations of such bnAbs could produce effective long-
term control of HIV-1 viremia and could be used for human
beings as well. In a study by Barouch et al. [30], PGT121,
3BNC117, and b12 were administered in doses of 10mg/kg to
SHIVSF162P3 infected rhesus monkeys. There was significant
and long-term control of viremia in animals with low baseline
viral loads (<3.5 log RNAcopies/mL), intermediate but short-
term control of viremia in animals with intermediate viral
loads (3.5–5.3 log RNA copies/mL), and incomplete control
and rapid rebound viremia in animals with high baseline viral
loads (>5.3 log RNA copies/mL).The study shows that bnAbs
though effective for HIV treatments have ceiling effects and
cannot be used as a solemodality for treatment and need to be
reinforced with antiretroviral medications. In another study
by Shingai et al. [31], 3BNC117 and 10-1074 blocked infection
and suppressed viremia in macaques infected with R5 tropic
SHIV-AD8. However, both the therapies resulted in rebound
viremia by day 10 and day 20, respectively, of treatment
initiations. Single genome amplification (SGA) studies later
confirmed that the virus mutated and lost the gp120 Asn 332
glycan in both of the antibody treated animals rendering the
virus resistant to both the antibody treatments. Table 2 shows
broadly neutralizing antibodies, target sites, and their breadth
of neutralization.
5. Coevolution of Broadly
Neutralizing Antibodies
The neutralizing antibodies in the HIV infection should be
able to cope with a number of immune evasion strategies
acquired by the viruses. The majority of the neutralizing
antibodies are directed towards the Env, which the viruses
keep mutating to evade the host immune responses [41].
To overcome this phenomenon, successful vaccines should
induce antibodies that are capable of binding andneutralizing
a broad spectrum of circulating viral products [42]. Such
bnAbs are found only in a small percentage of natural
infection and a set of host and viral factors mediate the
development as well as the breadth and potency of bnAbs.
Host responses include the genetic propensity towards stim-
ulating and utilizing VH gene, which are typically found
in the allele IGHV1-2∗02. Allelic differences in activation
of VH gene explain the existence of different branches of
somatic hypermutations from common germline sequences.
In HIV infected individuals with IGHV1-2∗02 alleles, the
somatic hypermutation is geared towards production of
useful bnAbs [33, 35]. Future vaccine trials should focus on
Journal of Immunology Research 5
Table 2: Broadly neutralizing antibodies, target sites, and breadth of neutralization.
Broadly neutralizing
antibodies Target site
Breadth of neutralization
(IC
50
< 50 𝜇g/mL) Study
VRC01 CD4 binding site 89% of 180 isolates Huang et al. (2012) [32]
VRC02 CD4 binding site 91% of 190 isolates Wu et al. (2010) [33]
VRC03 CD4 binding site 57% of 190 isolates Wu et al. (2010) [33]
VRC-PGV04 CD4 binding site 88% of 162 isolates Walker et al. (2011) [34]
VRC-PGV04b CD4 binding site 71% of 178 isolates Wu et al. (2011) [35]
CH103 CD4 binding site 55% of 196 isolates Liao et al. (2013) [22]
2F5 gp41 39% of 92 isolates Corti et al. (2010) [36]
2G12 gp120 41% of 90 isolates Binley et al. (2004) [37]
4E10 gp41 98% of 162 isolates Walker et al. (2009) [38]
PG9 V1-V2 loops 78% of 180 isolates Huang et al. (2012) [32]
PGT130 V3 loop 52% of 162 isolates Walker et al. (2011) [34]
PGT151 gp120-gp41 66% of 117 cross-clade isolates Bonsignori et al. (2014) [39]
PGT152 gp120-gp41 64% of 117 cross-clade isolates Blattner et al. (2014) [40]
Source: http://www.hiv.lanl.gov/.
stimulating VH genes for effective bnAbs production. Other
important host factors include the number of circulating
and functional CD4 T cells in peripheral blood as well as
germinal centers where the affinity maturation occurs. CD4
T follicular helper cells are necessary for B cell activation
and production of germinal centers [43]. In a study among
HIV positive participants, a specialized subpopulation of
circulatingmemory PD-1+CXCR5+ CD4T cells in peripheral
blood was also positively associated with bnAbs production
[44]. Several viral factors are also associated with production
of bnAbs. BnAbs are generally produced in patients with
moderate and sustained viral load [42, 45]. Furthermore,
viruses should undergo a specific number of mutations of
Env epitope targets after the development of precursors of
bnAbs. Only then would bnAbs mature through a specific
sequence of somatic hypermutations and retain the germ line
sequences and affinity for target sites. Thus it is a complex
interplay of host antibody acquisition potentials and ever-
evading viral mutations that generate and sustain useful
neutralizing bnAbs. A few studies have tried to explain the
evolution of bnAbs responses in HIV positive patients as well
as understand themechanisms bywhich bnAbs are produced.
In a study done by Liao et al. [22], it was found that bnAb
CH103 neutralized approximately 55% of HIV-1 products.
This study also found that a cocrystal bound structure of
CH103 bnAbs and gp120 produced increased affinity for CD4
binding site and the right sequence of somatic hypermu-
tation for production of bnAbs. This study further showed
that extensive viral diversification of CH103 epitope facili-
tated increased neutralization breadth of existing antibodies.
CH103 epitope constitutes an important target for vaccination
schedules to induce useful neutralizing bnAbs. A subsequent
study by Fera et al. [46] further explains the evolution of
bnAbs in HIV infected individuals. According to this study,
bnAb CH103 interacted with gp120 through heavy-chain
complementarity determining region 3 (CDRH3) to produce
conformational changes in the orientations of heavy and light
chains and thereby produced increased viral neutralization
response.This study opines that channelizing the continuous
struggle between virus and host immune responses could
help scientists to develop effective vaccines that stimulate
useful bnAb production.
6. Antibody-Dependent Cell-Mediated
Cytotoxicity (ADCC) and
Antibody-Dependent Cell-Mediated
Viral Inhibition (ADCVI)
Controlled viral load and better immunological profiles were
achieved through potent and persistent ADCC and ADCVI
[47, 48]. Both ADCC and ADVI are initiated by HIV-1
binding antibodies attaching to the Fc receptors of natural
killer (NK) cells, enabling them to destroy infected cells
expressing theHIV viral antigens [49].The strength ofADCC
is measured by the ability of NK cells to destroy HIV infected
cells. Similarly, ADCVI is measured by the ability of virus-
specific antibodies and NK cells to control or inhibit HIV
viral replication in a population of infected cells. Both ADCC
and ADCVI are mediated by antibodies that develop early
in the course of infection and have a broad neutralizing
spectrum enabling NK cells to have better reactivity profiles
in the initial stages of HIV infection [50]. However, the
viral replication rate and associated mutations outpace the
rates of ADCC and ADCVI activity thereby establishing the
infection in the target cells. Majority of the studies focusing
on HIV vaccines are directed towards accelerating the pace
of ADCC and ADCVI before the virus gets mutated thereby
increasing the elimination of HIV before it establishes in
the host cells [51]. In a study by Asmal et al. [52] on SIV
infected rhesus macaques, effective ADCVI inhibited SIV
replication by 100 times. This was observed during the first 3
weeks of SIV infection before the development of ineffective
plasma antibodies having low affinity for the mutated virus.
6 Journal of Immunology Research
Many of the mutated SIV envelope glycoproteins during late
stages of the infection were susceptible to ADCVI activity
though they were immune to plasma neutralization. This
study showed that SIV with mutated envelope glycoproteins
could not escape ADCC and ADCVI [52]. In a human study,
antibodies responsible for ADCC and ADCVI provided pro-
longed protections fromHIV-1 strains thereby controlling the
infection and affording long-term immunity [53]. In another
study, it was found that increased ADCC andADCVI activity
had reduced the risk of vertical transmission in women with
high viral loads. This study also showed that these antibodies
were transferred to the infants through breast milk [54].
7. Stimulation of CD8 T Cells
Immune Responses
Another broad arm of vaccine development studies includes
eliciting HIV specific CD8 T cell responses. CD8 T cells
destroy viruses and infected cells thereby helping in the
process of convalescence in any viral infection. This mecha-
nism does not work with HIV because CD8 T cells control
the viremia but cannot eliminate it [55]. In a study done
by Barouch et al. [56], it was found that DNA vaccines
elicited potent CD8 T cell responses and stable CD4 T cell
counts which were improved by purified fusion protein IL-
2/Ig. However, the STEP trial which administered MRKAd5
HIV-1 gag/pol/nef trivalent vaccine failed to show similar
results and rather increased the risk for HIV infection [57].
Similarly, in the HVTN 505 trial, stimulation of CD8 T cells
failed to show any protective effects on HIV infection [18].
Failure of these trials challenged the very concept of CD8
T cells immune responses for prevention of HIV. In spite of
such disappointing results, recent studies have focused some
viral vectors for stimulating and sustaining useful CD8 T
cell activity. Vaccination with SIV protein-expressing rhesus
cytomegalovirus (RhCMV/SIV) vectors offered long-term
control over viral load through stimulation of CD8 T cells
immune responses. For example, in a study done byHansen et
al. [58], it was observed that virus specific effector memory T
cellsmaintained through effective vectors completely stopped
the replication of SIV infection and also maintained notable
over time immune surveillance. This study suggests that
vaccines targeting effector memory T cells could possibly
afford functional cure and eradication of HIV infection as
observed in SIV infected rhesus macaques. Thus, we see that
CMV vectors induce uninterrupted, powerful, and long-term
antiviral immune surveillance over SIV infection and they
are promising candidate for vaccine development studies not
only for HIV but also for other viral diseases.
Recent advances in T cell based vaccines have focused on
incorporating the near complete gene sequences of several
proteins expressed by the viral strains in HIV controllers.
These composite immunogens aim at maximizing the incor-
poration of variable viral epitopes or mosaics [59]. Another
vaccine strategy includes avoiding all variable viral epitopes
and incorporating only conserved regions [60]. In a study
among rhesus monkeys, it was observed that the mosaic anti-
gens incorporating several phenotypes ofHIV-1Gag, Pol, and
Env antigens administered through replication-incompetent
adenovirus serotype 26 vectors markedly increased the depth
and breadth of T lymphocyte responses [59]. In a humans
study, vaccines incorporating the conserved regions of HIV-
1 proteome induced T cells which recognized infected CD4
cells and decreased HIV-1 viral replication [60]. Both the
studies independently show the importance of either con-
struct for successful vaccine development strategies through
advanced targeting of HIV viral proteome.
8. Viral Vectors, Alternative Delivery Systems,
and Costimulatory Molecules
Anumber of viral vectors and alternative delivery systems are
being researched for advanced HIV vaccines. These include
vectors such as nonreplicating adenovirus (Ad), adeno-
associated virus (AAV), Venezuelan equine encephalitis virus
(VEE), Sindbis virus (SIN), herpes simplex virus (HSV),
Measles virus (MV), modified vaccinia virus Ankara (MVA),
vesicular stomatitis virus (VSV), canarypox (ALVAC), Sem-
liki forest virus (SFV), DNA vectors, mRNA vectors, and
nanoformulations [61]. Table 3 shows examples of viral vec-
tors and alternative HIV vaccine delivery systems.
Costimulatory molecules provide secondary signals for
additional activation of T cells for increasing vaccine medi-
ated immune response. For example, costimulatory molecule
B7.2 delivered through the vector HIV pCgag/pol enhanced
the functioning of cytotoxic T lymphocytes [62]. Similarly,
TNF superfamily ligands (TNFSFL) have been shown to
improve the efficacy of ALVAC HIV-1 vaccines in a Phase III
clinical trial [63]. Several other costimulatory molecules are
being researched for increasing the efficacy of newer vaccines.
9. Future Challenges and Directions
In summary, we can say that there are several unanswered
questions from many failed as well as marginally successful
studies. A number of studies have identified potential epi-
topes for bnAbs which include V1/V2, V3 glycan, and CD4
binding site. The most important challenge is which of these
epitopes need to be targeted by future vaccines. The further
question is whether vaccines should focus on individual
epitopes or a combination of multiple epitopes. Researchers
should also focus on the breadth, magnitude, and durabil-
ity and other characteristics that make bnAbs significantly
neutralizing and useful. Future studies should also focus on
elucidating the right sequence of somatic hypermutations to
derive effectively neutralizing bnAbs. The phenomenon of
inducing somatic hypermutation through vaccination itself
is not fully understood and requires further research. Even
in studies showing marginal effects, the long-term efficacy of
vaccines is questionable.This factor is very important because
HIV/AIDS is becoming a chronic disease with increasing
prevalence, long number of infected years, and associated risk
for transmission. Vaccines therefore need to be effective in
the long term and offer continuous protection. With regard
to stimulation of cytotoxic T cells, the exact mechanism for
the production of effective CD8 T cell responses needs to
be researched and understood. Furthermore, results obtained
from studies on rhesus macaques with SIV viral proteins
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Table 3: Examples of viral vectors and alternative HIV vaccine delivery systems.
Examples of vectors Examples of vaccine
Nonreplicating adenovirus vectors (Ad) Mixture of 4 rAd5 vectors that express HIV-1 subtype B Gag-Pol fusionprotein and envelope (Env) from subtypes A, B, and C
Adeno-associated virus (AAV) Adeno-associated virus based HIV-1 subtype C vaccine (tgAAC09)
Venezuelan equine encephalitis virus (VEE) Sindbis virus
(SIN) Recombinant trimeric HIVΔV2gp140Env protein
Herpes virus (HSV) Recombinant herpes simplex virus (HSV) envelope and Nef antigens ofsimian immunodeficiency virus
Measles virus (MV) Recombinant measles virus vaccines expressing HIV-1 clade B envelopeglycoprotein
Modified vaccinia virus Ankara (MVA) Modified vaccinia virus Ankara-vectored HIV-1 clade A vaccine
Vesicular stomatitis virus (VSV) Recombinant vesicular stomatitis virus- (rVSV-) based vectorsexpressing HIV-1 env 89.6P gp160
Canarypox (ALVAC) HIV-1 canarypox vaccine (vCP1452)
Semliki forest virus (SFV) Self-amplifying rSFV2gen RNA encoding HIV-1C antigens
DNA vectors HIV-1 env/rev DNA vaccine
mRNA vectors MS2 VLP-mediated RNA vaccine
Nanoformulations
Fullerenol: nanoformulation of virus sized nanoparticles with
dual-function nanoadjuvants to simulate immune responses to the HIV
DNA vaccine
embedded on CMV vectors cannot be entirely expected to
produce analogous results in HIV viral proteins embedded
vector vaccines in human beings due to the phylogenetic
differences between simian and human immunodeficiency
viruses. Finally, the very emergence and continuous evolution
of innumerable number of quasi-species of HIV with diversi-
ties in genetic sequences and expressed surface glycoproteins
pose great challenges for HIV vaccines.
10. Conclusion
Many new immunological and virologicalmarkers like provi-
ral DNA levels in reservoir cells,measures of functional T and
B cell subsets, markers of biochemical and cellular immune
response, viral transmission rates, and viral neutralization
rates should be used in future studies to evaluate efficacy out-
comes in large-scale studies.This is especially challenging for
existing researchers and funding institutions because newer
paradigms are being proposed and discarded rapidly and
research on these paradigms is expensive and complicated.
The more time and money we invested in large-scale studies,
the closer we are to a successful vaccine. The governments of
different nations should cooperate together in meeting these
investments for a cause that could ultimately save millions of
lives as well as the money spent on managing and treating
HIV/AIDS. Only then can HIV/AIDS be controlled even in
the poorest nations across the globe and hopes of eradication
in the future would become a reality.
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